Viewing StudyNCT02196857

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 3:03 AM
Last Modification Date: 2024-10-26 @ 11:27 AM
Study NCT ID: NCT02196857
Status: COMPLETED
Last Update Posted: 2020-01-14
First Post: 2014-07-18
Brief Title: Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia AML and High Risk Myelodysplastic Syndrome MS With FLT3-ITD Mutation
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Leukemia
Keywords:
Name View
BAY 43-9006 View
Leukemia View
Acute myeloid leukemia View
AML View
High risk myelodysplastic syndrome View
MDS View
FLT3-ITD mutation View
Azacytidine View
5-Azacytidine View
5-AZA View
Vidaza View
5-AZC View
AZA-CR View
Ladakamycin View
NSC-102816 View
Sorafenib View
Nexavar View